|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Kimberly Park, Vice President Sales and Marketing, PriCara, Ortho-McNeil Janssen Pharmaceuticals

S

Kimberly Park

Vice President Sales and Marketing PriCara, Ortho-McNeil Janssen Pharmaceuticals

TRACK RECORD: Led Merck's managed care group and HIV/AIDS franchise

STARTED OUT: In SmithKline Beckman's management training program

We all have our moments. For Kimberly Park, her moment came when she decided to stay in her high-ranking job—and take on the additional task of being a mother. At first, she says, she wasn't confident that she would be able to manage her priorities. "But I soon realized that I could contribute at the same level—maybe even a higher level—because I became more focused. It was a chance for me to say, 'I'm not perfect, but I can do both.'" Now, Park co-chairs the Women's Leadership Initiative at J&J, where she heads up the company's primary care group. As for the affinity group, Park is proud to note that it's earned it stripes—and it's working. Meanwhile, women in other pharmas have taken a cue, and have set up similar groups at their own companies.

Kimberly Park

Articles in this issue

over 18 years ago

Mary Szela, Abbott

over 18 years ago

Mightier Than the Sword

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Nancy Phelan, Wyeth

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Wendy Niebler, Shire

over 18 years ago

Perfectly Imperfect

over 18 years ago

Relaunching Reform

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.